Abstract
Objective:
Bone is one of the most common sites of metastasis for breast cancer. The classification of new osteoblastic lesions as progressive disease is currently controversial. Computed tomography (CT), specifically the bone window setting, is the most frequently utilized for evaluating treatment efficacy in bone metastatic breast cancer (MBC). In this study, we aimed to assess the clinical features and significance associated with bone pseudoprogression.
Methods:
This retrospective analysis was conducted among twenty-three MBC patients with new osteoblastic lesions during the first-line systemic therapy in Jiangsu Cancer Hospital from January 2018 to December 2023. After assessing treatment response every two cycles by CT (bone window) at least twice, we identified no disease progression in participants, thus defining new osteoblastic lesions as bone pseudoprogression. Participants continued treatment until explicit disease progression was observed (extraosseous disease progression or progressive lysis on bone lesions). Pretreatment baseline and follow-up alkaline phosphatase (ALP) levels were analyzed separately at the times of bone progression and pseudoprogression in the same patient.
Results:
The spine (78.2%) was the predominant metastatic site. The median time to the appearance of bone pseudoprogression after treatment was 1.73 months (95% CI: 1.42-2.04). Furthermore, the median interval between bone pseudoprogression and disease progression was 14.27 months (95% CI: 12.18-16.35). No significant difference in the interval was observed between HER2-positive and HER2-negative MBC patients (15.83 months versus 14.23 months, p=0.79). Compared to the occurrence of disease progression, the levels of ALP decreased or stabilized at pseudoprogression in the same patient. The difference in ΔALP between pseudoprogression and progression was statistically significant (-20U/L vs. 33 U/L, p< 0.001).
Conclusions:
Osteoblastic new lesions detected using CT (bone window) may be considered bone pseudoprogression, which predominantly occurs in the early stages of treatment. ALP serves as a biomarker for differentiating pseudoprogression from disease progression on CT (bone window) in patients with bone metastasis. Clinicians should exercise caution regarding the appearance of new osteoblastic lesions in patients not exhibiting extraosseous disease progression or progressive lysis on bone lesions.
1 Introduction
Bone is one of the most common sites of metastasis for breast cancer. Approximately 80% of patients with metastatic breast cancer (MBC) develop bone metastases over the disease course (). Complications of bone metastasis include bone pain, spinal cord compression, pathologic fractures, and hypercalcemia, all of which can significantly impair the quality of life and the survival rate of patients (). Furthermore, breast cancer with bone metastases is often considered incurable. The optimal treatment is aimed that delay bone metastasis progression, alleviate pain, prevent skeletal-related events (SREs), and enhance the quality of life ().
Currently, no universally recognized standard exists for evaluating the efficacy of treatment for bone metastases in breast cancer, which are often deemed “unmeasurable” (). Bone scans (BSs) are commonly utilized for identifying metastases at an earlier stage and monitoring whole-body bone metastasis (). However, because of low specificity, BSs can produce false-positive results. Despite improvements in extraosseous lesions and decreased tumor markers among MBC patients during systemic therapy, new osteoblastic lesions, confirmed by CT, paradoxically appeared on BSs and improved on subsequent scans (, ). Professor Zhang et al. initially defined this phenomenon as bone pseudoprogression (). The bone pseudoprogression can be misinterpreted as disease progression, which may precipitate premature changes in systemic therapy regimens, impacting both treatment strategies selection and the duration of effective drugs use.
Consequently, the comprehensive application of various imaging techniques to accurately distinguish between bone pseudoprogression and disease progression is important in evaluating the efficacy of treatment for bone metastasis in breast cancer. Fluorodeoxyglucose F 18 ([18F]FDG) positron emission tomography/computed tomography (18F-FDG PET/CT), CT, and magnetic resonance imaging (MRI) are conventional approaches for assessing bone metastases. CT scans, particularly bone window scans, significantly contribute to evaluating treatment responses (), and surpass BSs in detecting bone disease (). Hence, we defined bone pseudoprogression as the appearance of new osteoblastic lesions on CT (bone window) in the absence of extraosseous disease progression, and no additional new lesions observed on subsequent CT (bone window) at least twice.
Previous studies have endeavored to differentiate bone pseudoprogression from disease progression using biochemical bone markers, such as osteocalcin, cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and serum tartrate-resistant acid phosphatase 5b (TRACP5b) (). However, these markers have not yet been clinically implemented. Among the various biochemical bone markers, alkaline phosphatase (ALP) is clinically accessible and instrumental in assessing responses to systemic therapy for bone metastasis ().
In this study, we aimed to assess the clinical features and significance associated with bone pseudoprogression, and to determine if ALP can effectively distinguish between bone pseudoprogression and disease progression in clinical practice.
2 Materials and methods
2.1 Data source and study population
We collected data from twenty-three MBC patients who received first-line treatment in Jiangsu Cancer Hospital from January 2018 to December 2023. The patients were characterized by the presence of new osteoblastic lesions in the absence of extraosseous disease progression during the first-line treatment. All patients received the standard first-line treatment recommended by the guidelines ().
2.2 Procedures and assessment
All the patients continued treatment until definitive disease progression was observed (extraosseous disease progression or progressive lysis on bone lesions). Extraosseous disease was routinely assessed at baseline and every two cycles by CT or MRI, in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (). CT (bone window) was performed at baseline and every two cycles to evaluate bone lesions.
Bone pseudoprogression was defined as the appearance of new osteoblastic lesions on CT (bone window) without extraosseous disease progression, and no additional new lesions on subsequent CT (at least twice).
Serum ALP levels were routinely measured during the cycle of systemic therapy. ALP was measured using an enzyme method (Roche Automatic Analyzer Cobas8000 c702; Roche, Germany). Patients were divided into two groups based on the presence or absence of previous bone metastatic lesions. For those with a history of bone metastasis, baseline and follow-up ALP levels were analyzed separately at the time of bone metastasis and bone pseudoprogression. The interval between examination of CT (bone window) and ALP was less than 10 days. The difference between baseline and follow-up ALP was denoted as ΔALP; ΔALP = follow-up ALP minus baseline ALP; ΔALP ratio = “ΔALP”/”baseline ALP” × 100 (%); “increased ALP” was defined as an increase in ΔALP ratio of more than 10% of baseline; “Decreased ALP” was defined as a decrease in ΔALP ratio of more than 10% of baseline; “Stable ALP” was defined as the remainder, being neither increased ALP nor decreased ALP ().
2.3 Statistical analysis
Statistical analyses were conducted using R Studio. The Kaplan–Meier curves were employed for analyzing the median interval between bone pseudoprogression and disease progression, and stratified log-rank tests were utilized to obtain P values between subgroups. ΔALP were compared statistically using the Mann–Whitney U test. P value<0.05 was considered indicative of statistical significance.
3 Results
3.1 Patient characteristics
This retrospective analysis was conducted among twenty-three MBC patients who developed new osteoblastic lesions during the first-line systemic therapy, without extraosseous disease progression. All patients continued their treatment regimens and assessed bone lesions every two cycles by CT (bone window). Additionally, CT or MRI was used to assess extraosseous disease every two cycles. As a result, extraosseous lesions of these patients had partial response (PR) or stable disease (SD) and no additional new lesions on subsequent CT (bone window) were included in this study (Figure 1).
Figure 1
Baseline characteristics are summarized in Table 1. The median age was 52 years (range, 36–70 years). The represented breast cancer molecular subtypes included HER2‐positive (14 of 23, 60.9%), HR‐positive/HER2‐negative (8 of 23, 34.8%), and triple‐negative breast cancer (1 of 23, 4.3%). Among them, 52.2% of patients had visceral metastasis, and 60.9% of these patients had pre-existing metastatic bone lesions. All patients received standard adjuvant and advanced first-line therapy based on different molecular subtypes, and no one received radiotherapy for bone lesions. Nearly all patients (91.3%) received bone-modifying agents, either previously or concurrently, including 78.3% of patients treated with zoledronic acid and 13.0% of patients treated with denosumab.
Table 1
| Characteristics | Number of patients (%) (N=23) |
|---|---|
| Age, years, median (range) | 52(36-70) |
| ECOG performance status | |
| 0 | 5(21.7) |
| 1 | 18(78.3) |
| Histological subtype | |
| Invasive ductal | 14(60.9) |
| Lobular | 2(8.7) |
| Other or not reported | 7(30.4) |
| Molecular subtype | |
| HER2-positive | 14(60.9) |
| HR-positive/HER2-negative | 8(34.8) |
| Triple negative | 1(4.3) |
| TNM stage at initial diagnosis of cancer | |
| I | 1(4.3) |
| II | 11(47.8) |
| III | 6(26.1) |
| IV | 5(21.7) |
| Metastatic organ sites | |
| Bone | 23(100) |
| Lung | 5(21.7) |
| Liver | 7(30.4) |
| Brain | 3(13.0) |
| Lymph nodes | 14(60.9) |
| Chest wall recurrence | 1(4.3) |
| Pleura | 3(13.0) |
| Visceral metastasis | |
| No | 11(47.8) |
| Yes | 12(52.2) |
| Bone-only metastasis | |
| No | 20(87.0) |
| Yes | 3(13.0) |
| Prior bone metastasis | |
| No | 10(39.1) |
| Yes | 13(60.9) |
| Number of metastatic organ sites | |
| ≤3 | 18(78.3) |
| >3 | 5(21.7) |
| Prior radiotherapy | |
| No | 23(100) |
| Yes | 0 |
| First-line therapy regimen | |
| Chemotherapy | 19(82.6) |
| Endocrine therapy(including CDK4/6i) | 8(34.8) |
| HER2-targeted therapy | 14(60.8) |
| Prior or concomitant bone-modifying agent | |
| Zoledronic acid | 18(78.3) |
| Denosumab | 3(13.0) |
| None | 2(8.7) |
Baseline patient characteristics.
3.2 Characteristics of bone metastatic lesions
Whether pre-existing bone metastases or new osteoblastic metastases, the predominant metastatic site was the spine (69.2% or 78.2%), particularly the thoracic and lumbar spine, followed by the pelvis (53.8% or 60.9%), ribs (7.7% or 17.4%), and long bones(7.7% or 4.3%). In addition, 17.4% of new osteoblastic metastases were presented in the sternum and 8.7% in the scapula compared to pre-existing osteolytic and mixed bone metastases (without bone lesions in the sternum and scapula). 61.5% and 73.9% patients had more than two pre-existing and new osteoblastic bone lesions, respectively. The characteristics of the bone metastatic lesions are summarized in Table 2.
Table 2
| Characteristics of bone metastatic lesions | Number of patients (%) | |
|---|---|---|
| Pre-existing bone metastatic lesions (N = 13) | New osteoblastic lesions (N = 23) | |
| Type of lesion | ||
| Osteosclerotic | 0 | 23(100) |
| Osteolytic | 6(46.2) | – |
| Mixed | 7(53.8) | – |
| Sites of lesions on skeleton | ||
| Ribs | 1(7.7) | 4(17.4) |
| Long bones | 1 (7.7) | 1 (4.3) |
| Pelvis | 7 (53.8) | 14 (60.9) |
| Sternum | 0 | 4(17.4) |
| Scapula | 0 | 2(8.7) |
| Spine | 9(69.2) | 18(78.2) |
| Cervical vertebra | 2(15.4) | 3(13.0) |
| Thoracic vertebra | 6(46.2) | 16(69.6) |
| Lumbar vertebra | 6(46.2) | 13(56.5) |
| Sacral vertebra | 7(53.8) | 5(21.7) |
| Total number of new lesions | ||
| 1–2 | 6(46.2) | 6(26.1) |
| >2 | 8(61.5) | 17(73.9) |
Characteristics of bone metastatic lesions.
3.3 Effects of new osteoblastic lesions on efficacy of treatment
The median follow-up was 23.0 months (range, 2.8-24.3 months) as of the data cutoff date in February 2024. At that point, seven patients (30.4%) were still receiving the first-line treatment, thirteen patients (56.5%) had discontinued treatment due to extraosseous disease progression, and three patients (13.0%) had experienced progression of bone lesions (Figure 2A).
Figure 2
The median time to the appearance of bone pseudoprogression after treatment was 1.73 months (range, 0.57-15.67 months). Among them, nineteen patients (82.6%) with MBC showed bone pseudoprogression within the first 3 months after treatment (Figure 2A).
In addition, the median interval between bone pseudoprogression and disease progression was 14.27 months. For instance, a 65-year-old patient, diagnosed with hormone receptor-negative (HR-negative) and human epidermal growth factor receptor 2-positive (HER2-positive) MBC, received trastuzumab, pertuzumab, paclitaxel liposome and carboplatin as first-line therapy. The baseline CT scan revealed multiple metastases in supraclavicular and mediastinal lymph nodes and CT (bone window) presented no metastasis lesions on bone (Figures 3A A, D, G). Following two cycles of treatment, lymph node metastases regressed compared to the previous ones, but a new round-like high-density shadow with clear boundaries at the lower edge of the first lumbar vertebra (Figures 3A B, E). We considered the sclerotic nodule as bone pseudoprogression and continued the treatment regimen. Subsequent post-treatment CT scans showed no new bone metastases, and the previous osteoblastic lesion had decreased in density (Figures 3A C, F), while extraosseous lesions exhibited partial response (PR) (Figures 3A H, J). After 9.53 months, the patient remained on treatment without evidence of disease progression (Figure 3A). Additionally, we observed bone pseudoprogression in patients with previous osteolytic metastases (Figure 3B). The patient’s original osteolytic metastasis in the sternum exhibited increased sclerotization compared to baseline during the first-line treatment, whereas the CT bone window revealed a new, rounded hyper dense lesion at the lower margin of the T4. We maintained the treatment strategy and the subsequent CT follow-up three months later showed that the original sternal osteolytic metastases had progressed to further sclerotization and repair, the osteogenic metastases remained stable, and no new bone metastatic lesions were detected. And the enlarged lymph nodes in the left axilla had significantly regressed.
Figure 3
Besides, stratified by different molecular subtypes, the interval between bone pseudoprogression and disease progression was 15.83 and 14.23 months in HER2-positive and HER2-negative, respectively [p = 0.79, (Figure 2B). When comparing patients with or without prior bone metastasis, there was no statistically significant difference in the interval, although the group without prior bone metastasis had a longer interval time [17.07 versus 15.83 months, p = 0.28 (Figure 2C)].
3.4 ALP for distinguishing pseudoprogression from disease progression
Thirteen patients previously exhibited bone metastasis (including osteolytic or mixed lesions). Baseline and follow-up ALP levels were analyzed separately at the time of bone metastasis and bone pseudoprogression in the same patient.
The median pretreatment and post-treatment ALP levels in the time of progression were 78 (range, 47–140) and 107(range, 65–301) IU/L, respectively, while those in the event of pseudoprogression were 102 (range, 47–301) and 94 (range, 48–193) IU/L, respectively. The incidence of stable or decreased ALP was higher in the times of pseudoprogression than progression (10/13, 76.9% vs. 1/13, 7.7%). In addition, 61.5% of patients experienced a decrease in ALP levels exceeding 10% during pseudoprogression, whereas no patients in the progression group did. Figure 4A illustrates the direct changes in ALP levels in the same patients experiencing pseudoprogression and disease progression. ΔALP was significantly different between the events of progression and pseudoprogression (33 vs -20 U/L p< 0.001; Figure 4B).
Figure 4
4 Discussion
Whether new osteoblastic lesions are defined as progression is currently controversial. In this study, we find that new osteoblastic lesions may represent bone pseudoprogression in the absence of extraosseous disease progression, and evaluated the clinical characteristics of bone pseudoprogression and the change in ALP in each patient was informative for differentiating pseudoprogression from disease progression.
BSs are commonly utilized for identifying metastases at an earlier stage. However, the false-positive result observed in BSs may mislead clinical judgment (). In other words, even if the treatment is effective, the uptake of tracers may increase in the short term. As demonstrated by Song ST et al., BS can only serve as the routine initial screening for bone metastasis. It cannot diagnose bone metastasis nor evaluate the effect of drug therapy ().In this study, considering that CT scans are superior to BSs for detecting bone disease (), and CT(bone window)is the most frequently utilized for assessing treatment efficacy in bone metastatic breast cancer. We used CT (bone window) to assess bone metastatic lesions. However, no general consensus has been reached on the optimal imaging methods for monitoring the bone metastasis of breast cancer, and various imaging modalities have advantages and limitations (). BSs may identify metastases at an earlier stage. However, it has some disadvantages, such as low specificity, no indication of osteoblastic or osteolytic lesions, and no indication of bone destruction from breast cancer bone metastases (). CT is preferable for assessing bone morphology, whereas MRI is superior for detecting early marrow infiltration and the influences of bone metastases on surrounding tissues ().18F-FDG PET/CT can demonstrate changes in metabolic activity both pre-and post-treatment (), however, this method is not as intuitive as CT scanning of bone; Thus, it is not routinely recommended in clinical work and the diagnostic value for breast cancer patients with bone metastases needs to be further demonstrated. In our opinion, the best imaging modality to assess accurate response in bone metastasis is a combination of various imaging methods, and CT bone window allows us to compare the density and size change of the same bone metastasis site more visually before and after treatment.
The definition of bone pseudoprogression was first documented by Professor Zhang in HR+/HER2-MBC patients who received first-line CDK4/6i plus endocrine therapy (). To the best of our knowledge, all published articles about bone pseudoprogression in breast cancer have involved HR-positive patients who developed bone pseudoprogression during or after CDK4/6i plus endocrine therapy (, , ). Consequently, some scholars attribute this phenomenon to the utilities of CDK4/6i combined with endocrine therapy. Compared to earlier findings, we observed bone pseudoprogression not only in HR+/HER2-MBC patients treated with CDK4/6i, but also in HER2-positive and TNBC patients, who received standard first-line treatment as recommended by the guidelines. Therefore, we believed there was no direct connection between bone pseudoprogression and CDK4/6i combined with endocrine therapy. In previous studies, bone pseudoprogression has been reported in HR+/HER2-MBC patients, we speculate that this may be due to HR+/HER2- patients account for 65%–70% of breast cancer patients (). In addition, bone pseudoprogression was observed in patients both with and without previous bone metastasis (Figure 3). Therefore, we believed that new osteoblastic lesions represented bone pseudoprogression rather than disease progression when extraosseous lesions remained stable, regardless of whether the patients had a previous combination of osteolytic or mixed metastases.
A prospective study indicated that 75% of patients with MBC exhibited bone pseudoprogression during the first 3 months after treatment (). Therefore, we defined the patients who appeared osteoblastic lesions, but no additional lesions on subsequent CT at least twice (every two cycles) as bone pseudoprogression in our study. Consistent with these findings, our study demonstrate that bone pseudoprogression predominantly occurs early in the course of treatment, particularly at the initial CT (bone window) evaluation post-therapy (30.4%). After the occurrence of bone pseudoprogression, all patients in our study continued their treatment regimens, with a median interval of 14.27 months between bone pseudoprogression and disease progression. In clinical practice, when a patient develops progression without initiating subsequent treatment, the disease will rapidly progress in a short period of time. In our study, despite the development of new osteoblastic lesions, these lesions remained stable or even improved when the original regimen was maintained. From our point of view, the appearance of new osteoblastic lesions was not considered to be the progression of the disease. Conversely, the emergence of these lesions, indicative of osteoblastic repair, suggested that patients were responsive to therapy, thus warranting the continuation of the original treatment protocol.
Beyond reparative osteogenesis, numerous preclinical studies indicate that the osteogenic niche may initially facilitate early bone metastatic colonization (, ). During the early stages of breast cancer bone metastasis, stromal cells surrounding bone-colonizing tumor cells exhibit heightened osteogenic activity, forming specialized microenvironments through E-cadherin/N-cadherin-mediated heterotypic adheres junctions. This osteogenic niche activates Ca2+ signaling and mTOR signaling, collectively promoting metastatic progression (). Critically, our clinical observations of bone pseudoprogression do not contradict but rather complement these findings, revealing the dual dynamic role of bone microenvironments: while osteogenic niches support early metastatic seeding, effective systemic therapy (e.g., endocrine/targeted agents) reprograms mesenchymal stromal cells within these niches toward reparative osteogenesis. This phenotypic shift manifests radiographically as new sclerotic lesions characteristic of bone pseudoprogression. Notably, micrometastases may remain dormant within osteogenic niches for extended periods before triggering the vicious cycle of macrometastatic growth, creating therapeutic opportunities for interception (). A phase III clinical trial on postmenopausal endocrine-resistant breast cancer(76% of patients with bone metastases) revealed an increase in progression-free survival when everolimus was used in combination with exemestane, indicating that the mTOR inhibitor may efficiently inhibit the progression of metastatic colonization in bone (). Furthermore, preclinical studies demonstrate that osteoblast-derived Jagged1 promotes both bone metastatic seeding and chemoresistance (), but anti-Jagged1 therapy (e.g., clone 15D11) in combination with chemotherapy effectively nullifies this resistance mechanism, resulting in superior suppression of bone metastases. These findings position Jagged1 inhibition as a promising strategy for clinical development in both established bone metastases and prevention of early-stage relapse.
Bone formation markers such as ALP, osteocalcin, and ICTP are increased in patients with bone metastases (). Koizumi et al. reported that an obvious increase in ICTP indicated disease progression, while a slight change in ICTP indicated bone pseudoprogression (). Besides, the combined use of SQBSI and TRACP5b allows for the differentiation of genuine disease progression from bone pseudoprogression, as has been demonstrated (). ALP is localized in the membrane of osteoblasts and, thus, represents the activity of osteoblast (). In a previous study, the “change in ALP” was identified as a useful serologic marker for differentiating pseudoprogression from disease progression in breast cancer patients with bone metastasis (). In the progressive metastatic bone lesion, osteoclasts and osteoblasts tend to increase, which results in the formation of new destructive bone lesions (). Consequently, elevated levels of ALP were observed in patients with disease progression, while no significant change or even a decrease in ALP levels was noted in patients who responded to effective treatment. Our findings are consistent with those from earlier studies, the incidence of stable or decreased ALP was higher in the time of pseudoprogression than progression (10/13, 76.9% vs. 1/13, 7.7%).In breast cancer, a significant decrease in serum ALP activity has been observed post-surgery, which suggested that the primary cancer cells may contribute to increased ALP levels (). However, in our study, we compared ALP levels in the same patient at the time of occurrence of bone pseudoprogression and during the period of only bone lesions progression. The results suggested that assessing response to systemic therapy for bone metastasis should consider the change in ALP levels during therapy.
There were still a few limitations in this study, including being a single-center retrospective study with a small sample size. Although Bone is one of the most common sites of metastasis for breast cancer, osteoblastic metastases in breast cancer are relatively rare. Due to the small sample size, we could not determine the incidence of osteoblastic metastases from breast cancer. Additionally, because of the retrospective study design, evaluation was possible only for serum ALP, which was routinely obtained and it could not be assessed whether other markers could distinguish bone pseudoprogression from disease progression in clinical practice. To overcome these limitations, large prospective studies with comparative and combinatorial analyses using other markers are needed to explore these results further.
5 Conclusion
Regardless of whether there were prior osteolytic or mixed bone metastases, the presence of new osteoblastic lesions in the absence of extraosseous disease progression may consider as bone pseudoprogression, which occurs predominantly in the early stages of treatment. Clinicians should exercise caution regarding the emergence of osteoblastic metastases and avoid premature discontinuation of effective treatment due to misjudgments. Decrease or stabilization in ALP levels is recognized as a biomarker indicating the potential for bone pseudoprogression.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving humans were approved by The Ethics Committee of Jiangsu Cancer Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. This is a single-institution, retrospective study that received approval from the Ethics Committee of Jiangsu Cancer Hospital (KY-2024-088), and individual consent for this retrospective analysis was waived.
Author contributions
TX: Formal Analysis, Writing – review & editing, Writing – original draft, Data curation, Investigation. YM: Data curation, Formal Analysis, Writing – review & editing. LZ: Formal Analysis, Writing – review & editing. SL: Writing – review & editing, Formal Analysis. MD: Conceptualization, Writing – review & editing, Supervision, Project administration. YY: Supervision, Writing – review & editing, Data curation, Project administration, Conceptualization.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Acknowledgments
We gratefully acknowledge the support of the Jiangsu Cancer Hospital and their research teams at the participating sites. The Jiangsu Cancer Hospital served as the data source for this study.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Author disclaimer
The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the Jiangsu Cancer Hospital.
References
1
YinJJPollockCBKellyK. Mechanisms of cancer metastasis to the bone. Cell Res. (2005) 15:57–62. doi: 10.1038/sj.cr.7290266
2
RubensRD. Bone metastases–the clinical problem. Eur J Cancer. (1998) 34:210–3. doi: 10.1016/S0959-8049(97)10128-9
3
GnantMHadjiP. Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res. (2010) 12:216. doi: 10.1186/bcr2768
4
HamaokaTMadewellJEPodoloffDAHortobagyiGNUenoNT. Bone imaging in metastatic breast cancer. J Clin Oncol. (2004) 22:2942–53. doi: 10.1200/JCO.2004.08.181
5
CookGJRAzadGKGohV. Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med. (2016) 57:27S–33S. doi: 10.2967/jnumed.115.157867
6
JanicekMJHayesDFKaplanWD. Healing flare in skeletal metastases from breast cancer. Radiology. (1994) 192:201–4. doi: 10.1148/radiology.192.1.8208938
7
SchneiderJADivgiCRScottAMMacapinlacHASeidmanADGoldsmithSJet al. Flare on bone scintigraphy following taxol chemotherapy for metastatic breast cancer. J Nucl Med. (1994) 35:1748–52.
8
LinMJinYYangZHuXZhangJ. Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer. Ther Adv Med Oncol. (2021) 13:17588359211022881. doi: 10.1177/17588359211022881
9
WoolfDKPadhaniARMakrisA. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann Oncol. (2015) 26:1048–57. doi: 10.1093/annonc/mdu558
10
Even-SapirE. Imaging of Malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. (2005) 46:1356–67.
11
TsaiSH. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis. Mayo Clin Proc. (2007) 82:917–26. doi: 10.4065/82.8.917
12
JungJHHongCMJoIJeongSYLeeSWLeeJet al. Reliability of alkaline phosphatase for differentiating flare phenomenon from disease progression with bone scintigraphy. Cancers. (2022) 14:254. doi: 10.3390/cancers14010254
13
GradisharWJMoranMSAbrahamJAbramsonVAftRAgneseDet al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. (2024) 22:331–57. doi: 10.6004/jnccn.2024.0035
14
EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRet al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026
15
MengXYSongST. Evaluation and classification of drug therapy for breast cancer with bone-only metastasis. Chin J Oncol. (2017) 39:161. doi: 10.3760/cma.j.issn.0253.3766.2017.03.001
16
AzadGKSiddiqueMTaylorBGreenAO'DohertyJGarianiJet al. Is response assessment of breast cancer bone metastases better with measurement of 18 F-fluoride metabolic flux than with measurement of 18 F-fluoride PET/CT SUV? J Nucl Med. (2019) 60:322–7. doi: 10.2967/jnumed.118.208710
17
JiangZWangHWangSWangSSWangTWangXet al. Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease. Trans Breast Cancer Res. (2021) 2:2–2. doi: 10.21037/tbcr-20-65
18
Van EsSCVellemanTEliasSGBenschFBrouwersAHGlaudemansAWJMet al. Assessment of bone lesions with 18 F-FDG PET compared with 99m Tc bone scintigraphy leads to clinically relevant differences in metastatic breast cancer management. J Nucl Med. (2021) 62:177–83. doi: 10.2967/jnumed.120.244640
19
TianALvHLiuWZhaoJZhaoSWangKet al. Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report. Front Oncol. (2023) 12:1099164. doi: 10.3389/fonc.2022.1099164
20
HuangWLiCChenMLinDWuFChenXet al. Pseudoprogression after palbociclib with aromatase inhibitors treatment in metastatic breast cancer. OncoTargets Ther. (2020) 13:7785–92. doi: 10.2147/OTT.S253333
21
EggersmannTKDegenhardtTGluzOWuerstleinRHarbeckN. CDK4/6 inhibitors expand the therapeutic options in breast cancer: palbociclib, ribociclib and abemaciclib. BioDrugs. (2019) 33:125–35. doi: 10.1007/s40259-019-00337-6
22
ColemanREMashiterGWhitakerKBMossDWRubensRDFogelmanI. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med. (1988) 29:1354–9.
23
WangHTianLLiuJGoldsteinABadoIZhangWet al. The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell. (2018) 34:823–39.e7. doi: 10.1016/j.ccell.2018.10.002
24
WangHYuCGaoXWelteTMuscarellaAMTianLet al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. (2015) 27:193–210. doi: 10.1016/j.ccell.2014.11.017
25
BaselgaJCamponeMPiccartMBurrisHARugoHSSahmoudTet al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. (2012) 366:520–9. doi: 10.1056/NEJMoa1109653
26
ZhengHBaeYKasimir-BauerSTangRChenJRenGet al. Therapeutic antibody targeting tumor- and osteoblastic niche-derived jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. (2017) 32:731–47.e6. doi: 10.1016/j.ccell.2017.11.002
27
KoizumiMMatsumotoSTakahashiSYamashitaTOgataE. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med. (1999) 24:15–20. doi: 10.1097/00003072-199901000-00004
28
GolubEEBoesze-BattagliaK. The role of alkaline phosphatase in mineralization. Curr Opin Orthop. (2007) 18:444–8. doi: 10.1097/BCO.0b013e3282630851
29
ColemanRWhitakerKMossDMashiterGFogelmanIRubensRDet al. Biochemical prediction of response of bone metastases to treatment. Br J Cancer. (1988) 58:205–10. doi: 10.1038/bjc.1988.194
30
KhCKpyatiAMurthy DsJ. Significance of serum total alkaline phosphatase levels in breast cancer. Int J Clin Biomed Res. (2016) 2:13–5.
Summary
Keywords
breast cancer, bone metastasis, pseudoprogression, osteoblastic metastasis, alkaline phosphatase
Citation
Xu T, Ma Y, Zhang L, Li S, Dong M and Yuan Y (2025) Determination and clinical features of bone pseudoprogression in metastatic breast cancer. Front. Oncol. 15:1643179. doi: 10.3389/fonc.2025.1643179
Received
08 June 2025
Accepted
09 September 2025
Published
25 September 2025
Volume
15 - 2025
Edited by
Sharon R. Pine, University of Colorado Anschutz Medical Campus, United States
Reviewed by
Norma Alejandra Chasseing, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
Mingcang Chen, Chinese Academy of Sciences (CAS), China
Updates
Copyright
© 2025 Xu, Ma, Zhang, Li, Dong and Yuan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuan Yuan, yuanyuan810122@126.com; Min Dong, 13851670000@163.com
†These authors share first authorship
‡ORCID: Ting Xu, orcid.org/0009-0004-2138-0572; Yikun Ma, orcid.org/0009-0008-2253-5774; Lili Zhang, orcid.org/0000-0002-4646-6565; Shiyi Li, orcid.org/0009-0007-1630-6003; Min Dong, orcid.org/0009-0002-0400-3674; Yuan Yuan, orcid.org/0000-0002-2060-5969
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.